Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Recommendation of “Hold” by Analysts

Amicus Therapeutics, Inc. (NASDAQ:FOLD) has earned a consensus rating of “Hold” from the fourteen research firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $15.55.

Several brokerages have commented on FOLD. Cantor Fitzgerald downgraded shares of Amicus Therapeutics from an “overweight” rating to a “hold” rating and lowered their price objective for the company from $21.00 to $14.50 in a research report on Friday, December 19th. Wall Street Zen upgraded Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Zacks Research downgraded Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 26th. Citigroup reaffirmed a “neutral” rating and issued a $14.50 price objective (down from $17.00) on shares of Amicus Therapeutics in a research note on Monday, December 22nd. Finally, Guggenheim downgraded Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 5th.

Insider Activity at Amicus Therapeutics

In related news, insider Ellen Rosenberg sold 36,000 shares of the stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $10.00, for a total value of $360,000.00. Following the completion of the transaction, the insider owned 507,710 shares of the company’s stock, valued at $5,077,100. This represents a 6.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider David Michael Clark sold 25,643 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $10.10, for a total transaction of $258,994.30. Following the completion of the sale, the insider owned 296,975 shares in the company, valued at $2,999,447.50. This represents a 7.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 394,807 shares of company stock valued at $4,486,385 in the last quarter. 2.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Amicus Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Mercer Global Advisors Inc. ADV bought a new position in Amicus Therapeutics in the fourth quarter valued at about $242,000. Empowered Funds LLC acquired a new position in shares of Amicus Therapeutics in the fourth quarter valued at approximately $1,605,000. Zacks Investment Management bought a new position in Amicus Therapeutics in the 4th quarter valued at approximately $166,000. Vazirani Asset Management LLC bought a new position in Amicus Therapeutics in the 4th quarter valued at approximately $356,000. Finally, Superstring Capital Management LP acquired a new stake in Amicus Therapeutics during the 4th quarter worth approximately $5,025,000.

Amicus Therapeutics Price Performance

Shares of NASDAQ:FOLD opened at $14.34 on Thursday. The firm has a 50 day moving average of $13.85 and a 200-day moving average of $10.32. Amicus Therapeutics has a 12 month low of $5.51 and a 12 month high of $14.38. The company has a current ratio of 2.99, a quick ratio of 2.09 and a debt-to-equity ratio of 1.70. The stock has a market capitalization of $4.50 billion, a PE ratio of -358.41 and a beta of 0.38.

Amicus Therapeutics Company Profile

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.